Pheon Therapeutics

Pheon Therapeutics, founded in 2022, is a promising player in the biotechnology, health and wellness, and life sciences sectors, with headquarters in the United Kingdom. The company specializes in developing next-generation Antibody-Drug Conjugates (ADCs) to tackle hard-to-treat cancers, as highlighted by their slogan: "Pheon is an Antibody-Drug Conjugate specialist developing next generation ADCs for a range of hard-to-treat cancers."

Pheon's strategy hinges on leveraging two decades of ADC expertise to craft a unique pipeline aimed at solid tumors and liquid cancers unresponsive to current treatments. By utilizing both novel and validated monoclonal antibodies and experimenting with proprietary and off-the-shelf linkers, Pheon balances efficacy and safety. Their lead program focuses on a novel target relevant to numerous solid tumors, anticipating an Investigational New Drug (IND) application within 18 months.

In 2024, the company secured a substantial $120.00M Series B investment from TCGX, joining the ranks of other expert investors like Atlas Venture, Brandon Capital, Forbion, and Research Corporation Technologies. With state-of-the-art facilities in London and a commercial presence in Boston, Pheon Therapeutics is positioned for significant advancements in their quest to revolutionize cancer treatment.